Hb-022 Inc. specializes in enhancing bioavailability using its proprietary, licensed technology. The limited bioavailability of small molecule medicines is often compensated with higher dosages, resulting in undesirable metabolites side effects. Hb-022 has an exclusive license to a patent portfolio that focuses on enhancing bioavailability. Through our differentiated formulations, we have been able to significantly reduce the amount of active pharmaceutical ingredient (API) required while maintaining or even improving the efficacy of the drug. Another critical aspect of drug development is the patent life. The various stages, including IND, Phase I, and Phase II, are time-consuming, taking up to several years. However, at Hb-022, we have developed efficient processes and strong partnerships with accredited manufacturers and service providers. As a result, we have been able to reduce the timeline of IND to 9 months and Phase I and Phase II combined to 18 additional months. This significant time-saving provides our partners with significantly higher patent life, therefore increasing the valuation of the patents.